Innovent Biologics (IVBXF) News Today $4.71 -0.41 (-7.92%) As of 02:57 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Innovent Is Said to Consider Licensing Partnership for Cancer DrugMarch 11 at 1:01 AM | bloomberg.comHead-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in MelanomaMarch 2, 2025 | prnewswire.comNMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon CancerFebruary 23, 2025 | prnewswire.comInnovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung CancerFebruary 16, 2025 | prnewswire.comExploring High Growth Tech And 2 Other Prominent Stocks With PotentialFebruary 6, 2025 | uk.finance.yahoo.comInnovent Biologics: Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerJanuary 18, 2025 | finanznachrichten.deInnovent & ASK Pharm Announce NMPA Approval Of Limertinib,3rd-Gen EGFR TKI For Lung Cancer TreatmentJanuary 16, 2025 | markets.businessinsider.comInnovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerJanuary 16, 2025 | prnewswire.comInnovent Presents at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 16, 2025 | prnewswire.comInnovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic CancerJanuary 15, 2025 | prnewswire.comHigh Growth Tech Stocks Innovent Biologics And 2 Other Promising PicksJanuary 9, 2025 | finance.yahoo.comInnovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2025 | prnewswire.comInnovent wins second China nod for Nuvation-partnered cancer therapyJanuary 3, 2025 | msn.comInnovent Biologics: Strategic Partnerships and Robust Pipeline Drive Buy RatingJanuary 3, 2025 | markets.businessinsider.comRoche, Innovent ink licensing deal for lung cancer drugJanuary 2, 2025 | msn.comInnovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland ChinaDecember 16, 2024 | finance.yahoo.comInnovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024December 8, 2024 | prnewswire.comHUTCHMED Gains Approval for Innovative Cancer TherapyDecember 4, 2024 | msn.comInnovent Biologics Secures New Approval for Cancer TreatmentDecember 4, 2024 | markets.businessinsider.comInnovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug ListNovember 27, 2024 | prnewswire.comInnovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024November 24, 2024 | prnewswire.comClaudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial ProgressNovember 22, 2024 | globenewswire.comInnovent Ditches Low-Value Stake Sale After Investor OutcryNovember 7, 2024 | benzinga.comInnovent Biologics Inc.November 6, 2024 | wsj.comInnovent Biologics: Strong Sales Momentum and Growth Potential Drive Buy RatingNovember 6, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Innovent Biologics (IVBXF)October 31, 2024 | markets.businessinsider.comInnovent Biologics says picankibart phase 2 study met primary endpointOctober 29, 2024 | markets.businessinsider.comInnovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 BiologicsOctober 28, 2024 | prnewswire.comInnovent Biologics Sells Minority Stake in SubsidiaryOctober 25, 2024 | msn.comInnovent’s trial of picankibart for ulcerative colitis meets primary endpointOctober 18, 2024 | msn.comInnovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary EndpointOctober 16, 2024 | prnewswire.comInnovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerOctober 7, 2024 | prnewswire.comInnovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque PsoriasisSeptember 26, 2024 | prnewswire.comInnovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other ...September 19, 2024 | msn.comInnovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO CongressSeptember 17, 2024 | prnewswire.comInnovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO CongressSeptember 17, 2024 | prnewswire.comHead-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024September 11, 2024 | prnewswire.comInnovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLCSeptember 10, 2024 | prnewswire.comInnovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C MutationSeptember 9, 2024 | prnewswire.comInnovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced MelanomaSeptember 3, 2024 | prnewswire.comInnovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024September 1, 2024 | prnewswire.comInnovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024August 28, 2024 | prnewswire.comInnovent Announces 2024 Interim Results and Business UpdatesAugust 28, 2024 | prnewswire.comChina's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of ChinaAugust 21, 2024 | prnewswire.comInnovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)August 1, 2024 | prnewswire.comInnovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of ChinaAugust 1, 2024 | prnewswire.comInnovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and DevelopmentJuly 25, 2024 | prnewswire.comInnovent Biologics : Second Phase 3 Trial Of Mazdutide In Type 2 Diabetes Meets Study EndpointsJuly 22, 2024 | markets.businessinsider.comInnovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPAJuly 21, 2024 | prnewswire.comInnovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate ResponsibilityJuly 7, 2024 | prnewswire.com Remove Ads Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address IVBXF Media Mentions By Week IVBXF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVBXF News Sentiment▼-1.320.77▲Average Medical News Sentiment IVBXF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVBXF Articles This Week▼11▲IVBXF Articles Average Week Remove Ads Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today BRRGF News Today BCTXW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IVBXF) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredWarning: What they're not telling you about these recent selloffsIn light of massive recent selloffs... our senior analyst Dan Ferris has issued a new warning for the American...Stansberry Research | SponsoredSilent Raid on IRAs and 401(k)s Begins—Are You Next?Look around—everything feels oddly steady. Gas prices aren't skyrocketing. Banks aren't collapsing. The mar...Genesis Gold Group | SponsoredWarren Buffet Just Made a $334 Billion BetDebt is out of control. Inflation is creeping back. And a major market downturn could be right around the corn...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovent Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
